Comparative Pharmacology
Head-to-head clinical analysis: GLOFIL 125 versus PYLARIFY TRUVU.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLOFIL 125 versus PYLARIFY TRUVU.
GLOFIL-125 vs PYLARIFY TRUVU
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GLOFIL-125 (pentoxifylline) is a xanthine derivative that improves erythrocyte flexibility by inhibiting phosphodiesterase, leading to increased intracellular cAMP. It also reduces blood viscosity and platelet aggregation, improving microcirculation.
PYLARIFY is a PSMA-targeted PET imaging agent composed of a urea-based PSMA ligand (piflufolastat) labeled with fluorine-18. It binds to prostate-specific membrane antigen (PSMA) on prostate cancer cells, allowing PET imaging for detection of PSMA-positive lesions.
125 mg orally twice daily.
1 mg/kg intravenously every 3 months.
None Documented
None Documented
Terminal elimination half-life: 2.5–3.5 hours (prolonged in renal impairment; up to 20–30 hours in severe chronic kidney disease).
Terminal elimination half-life: approximately 77 hours (range 68-85 hours) in patients with prostate cancer. This supports a 2-week dosing interval for single-photon emission computed tomography (SPECT) imaging.
Renal excretion of unchanged drug >90%; biliary/fecal <5%.
Renal excretion: approximately 93% (3% unchanged, 97% as metabolites). Fecal excretion: approximately 5%. Biliary excretion is negligible.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical